论文部分内容阅读
目的:对恶性肿瘤患者接受免疫抑制剂后获得医院获得性肺炎进行研究。方法:我院在2015年1月至2016年1月1年间收治的恶性肿瘤患者500例在接受免疫抑制剂治疗后,其中有95例患者感染上了医院获得性肺炎。然后就治疗过程中合并医院获得性肺炎的患者的住院的病历进行研究分析,并总结出采用免疫抑制剂治疗会增加医院获得性肺炎发病率的原因。结果:在接受免疫抑制剂治疗后的500例恶性肿瘤患者感染医院获得性肺炎的概率为8.96%,再次感染感染率为11.23%。其中当白细胞大于3.0×10~9/L时,接受免疫抑制剂治疗后感染医院获得性肺炎的概率为3.85%,;当白细胞小于1.0×10~9/L时,接受免疫抑制剂治疗后感染医院获得性肺炎的概率为54.65%,再次感染感染率为78.23%。结论:血白细胞数量多少对恶性肿瘤患者应用免疫抑制剂治疗后合并感染医院获得性肺炎有影响。
OBJECTIVE: To study hospital-acquired pneumonia after receiving immunosuppressive agents in patients with malignant tumors. Methods: Five hundred and fifty patients with malignant tumors admitted to our hospital from January 2015 to January 2016 were immunosuppressed and 95 of them were hospital-acquired pneumonia. Then the medical records of hospitalized patients with hospital-acquired pneumonia in the course of treatment were analyzed and concluded that the use of immunosuppressive agents may increase the incidence of hospital-acquired pneumonia. Results: The incidence of nosocomial pneumonia was 8.96% in 500 patients with malignant tumor after immunosuppressive therapy and the rate of re-infection was 11.23%. When the white blood cell is greater than 3.0 × 10 ~ 9 / L, the probability of nosocomial pneumonia after receiving immunosuppressive therapy is 3.85%; when the white blood cells is less than 1.0 × 10 ~ 9 / L, the infection after receiving immunosuppressive therapy The probability of hospital-acquired pneumonia was 54.65%, and the rate of re-infection was 78.23%. Conclusion: The number of white blood cells in patients with malignant tumors after immunosuppressive therapy combined with the impact of hospital-acquired pneumonia.